Giant Cell Arteritis Gca clinical trials

Explore recruiting giant cell arteritis gca clinical trials.

Recruiting giant cell arteritis gca studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Giant Cell Arteritis Gca trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)

Estonia, Sweden, Hungary, Finland, France, Norway +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA)

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

Spain, Czechia, Portugal, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

French prospective open label phase II randomized non-comparative study of SC tocilizumab associated with IV pulse steroid versus IV pulse steroid alone for the treatment of acute anterior ischemic optic neuropathy associated with giant cell arteritis. (TOCIAION)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

RANDOMIZED, CONTROLLED, OPEN TRIAL OF TWO STANDARDIZED DECLINE SCHEMES, FAST (NORTH AMERICAN) AND SLOW (EUROPEAN) RESPECTIVELY, OF CORTISONE IN GIANT CELL ARTERITIS

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

REPLACE - A multi-centre, randomised, double-blinded, placebo controlled 16-weeks study to compare the effect of hydrocortisone and placebo in patients with Giant Cell Arteritis (GCA)/ Polymyalgia Rheumatica (PMR) with patient-reported symptoms of adrenal insufficiency after cessation of glucocorticoid treatment.

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Giant Cell Arteritis Gca trials by city

Giant Cell Arteritis Gca in Toronto Giant Cell Arteritis Gca in Vancouver Giant Cell Arteritis Gca in Montreal Giant Cell Arteritis Gca in Calgary Giant Cell Arteritis Gca in Edmonton Giant Cell Arteritis Gca in Ottawa Giant Cell Arteritis Gca in Winnipeg Giant Cell Arteritis Gca in Quebec City Giant Cell Arteritis Gca in Hamilton Giant Cell Arteritis Gca in Kitchener Giant Cell Arteritis Gca in London Giant Cell Arteritis Gca in Halifax Giant Cell Arteritis Gca in New York Giant Cell Arteritis Gca in Los Angeles Giant Cell Arteritis Gca in Chicago Giant Cell Arteritis Gca in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease